Symbols / NBP Stock $2.38 -3.64% NovaBridge Biosciences

Healthcare • Biotechnology • United States • NGM
NBP (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Xi-Yong Fu M.B.A., Ph.D.
Exch · Country NGM · United States
Market Cap 275.24M
Enterprise Value 425.28M
Income -88.34M
Sales —
FCF (ttm) -37.11M
Book/sh 2.00
Cash/sh 0.79
Employees 30
Insider 10d —
IPO Jan 17, 2020
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -2.25
PEG —
P/S —
P/B 1.19
P/C —
EV/EBITDA -4.51
EV/Sales —
Quick Ratio 7.91
Current Ratio 8.09
Debt/Eq 1.33
LT Debt/Eq —
EPS (ttm) -0.48
EPS next Y -1.06
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-14
Earnings (prior) 2026-04-07
ROA -24.90%
ROE -40.89%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 115.65M
Shs Float 148.64M
Insider Own 21.33%
Instit Own 42.13%
Short Float 8.34%
Short Ratio 4.57
Short Interest 4.34M
52W High 6.79
vs 52W High -64.95%
52W Low 0.83
vs 52W Low 185.71%
Beta 1.74
Impl. Vol. 1.13%
Rel Volume 2.12
Avg Volume 872.47K
Volume 1.85M
Target (mean) $8.00
Tgt Median $8.00
Tgt Low $7.00
Tgt High $9.00
# Analysts 3
Recom None
Prev Close $2.47
Price $2.38
Change -3.64%
About

NovaBridge Biosciences, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment of solid tumors. It has a strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell, and offer to sell FE301, an interleukin-6 inhibitor. The company also has collaborations with Bristol Myers Squibb for the development of givastomig; ABL Bio, Inc. for the development of givastomig and ragistomig; and TJ Bio for the development of uliledlimab. The company was formerly known as I-Mab and change its name to NovaBridge Biosciences in October 2025. NovaBridge Biosciences was founded in 2014 and is headquartered in Rockville, Maryland.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$8.00
Mean price target
2. Current target
$2.38
Latest analyst target
3. DCF / Fair value
$-5.78
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.38
Low
$7.00
High
$9.00
Mean
$8.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-08 reit HC Wainwright & Co. Buy → Buy $9
2026-03-16 reit HC Wainwright & Co. Buy → Buy $9
2026-02-06 main HC Wainwright & Co. Buy → Buy $9
2025-10-24 reit BTIG Buy → Buy $9
2025-10-17 main BTIG Buy → Buy $9
2025-10-03 init Leerink Partners — → Outperform $9
2025-09-10 reit BTIG Buy → Buy $7
2025-09-09 init BTIG — → Buy $7
2025-09-08 reit Needham Buy → Buy $6
2025-08-21 reit HC Wainwright & Co. Buy → Buy $7
2025-08-20 main Needham Buy → Buy $6
2025-07-09 reit HC Wainwright & Co. Buy → Buy $7
2025-07-09 reit Needham Buy → Buy $5
2025-06-27 main Needham Buy → Buy $5
News
RSS: Latest NBP news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-04-24 HAGLER MARK ARNOLD President — 230,000 $2.51 $577,300
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
-100.00%
0.63
+140.75%
-1.55
Operating Revenue
0.00
0.00
-100.00%
0.63
+140.75%
-1.55
Cost Of Revenue
—
—
0.00
-100.00%
3.95
Reconciled Cost Of Revenue
—
—
0.00
-100.00%
3.95
Gross Profit
—
—
3.90
+110.81%
-36.06
Operating Expense
94.27
+83.31%
51.43
+3.66%
49.61
-3.72%
51.53
Research And Development
62.91
+188.95%
21.77
+1.50%
21.45
-4.87%
22.55
Selling General And Administration
31.36
+5.76%
29.66
+5.31%
28.16
-2.83%
28.98
General And Administrative Expense
31.36
+5.76%
29.66
+5.31%
28.16
-2.83%
28.98
Other Gand A
31.36
+5.76%
29.66
+5.31%
28.16
-2.83%
28.98
Other Operating Expenses
—
-1.27
-68.54%
-0.76
+79.54%
-3.69
Total Expenses
94.27
+83.31%
51.43
+3.66%
49.61
-3.72%
51.53
Operating Income
-94.27
-83.31%
-51.43
-5.00%
-48.98
+7.73%
-53.08
Total Operating Income As Reported
-94.27
-83.31%
-51.43
+28.59%
-72.02
-35.68%
-53.08
EBITDA
-93.41
-85.17%
-50.45
-5.29%
-47.91
+7.25%
-51.66
Normalized EBITDA
-91.66
-103.26%
-45.09
-187.00%
-15.71
+31.63%
-22.98
Reconciled Depreciation
0.86
-12.47%
0.98
-7.82%
1.06
-25.02%
1.42
EBIT
-94.27
-83.31%
-51.43
-5.00%
-48.98
+7.73%
-53.08
Total Unusual Items
-1.76
+67.21%
-5.36
+83.37%
-32.20
-12.28%
-28.68
Total Unusual Items Excluding Goodwill
-1.76
+67.21%
-5.36
+83.37%
-32.20
-12.28%
-28.68
Special Income Charges
0.00
+100.00%
-13.63
+40.83%
-23.04
0.00
Other Special Charges
—
12.39
—
—
Impairment Of Capital Assets
0.00
-100.00%
1.25
-94.59%
23.04
0.00
Restructuring And Mergern Acquisition
—
12.39
0.00
0.00
Net Income
-46.27
-108.14%
-22.23
+89.30%
-207.73
+44.02%
-371.05
Pretax Income
-88.34
-77.76%
-49.70
+39.56%
-82.22
+41.73%
-141.10
Net Non Operating Interest Income Expense
7.61
+1.67%
7.49
-19.45%
9.29
+87.61%
4.95
Interest Expense Non Operating
—
—
0.10
+7707.99%
0.00
Net Interest Income
7.61
+1.67%
7.49
-19.45%
9.29
+87.61%
4.95
Interest Expense
—
—
0.10
+7707.99%
0.00
Interest Income Non Operating
7.61
+1.67%
7.49
-19.45%
9.29
+87.61%
4.95
Interest Income
7.61
+1.67%
7.49
-19.45%
9.29
+87.61%
4.95
Other Income Expense
-1.68
+70.78%
-5.76
+86.47%
-42.53
+54.25%
-92.98
Other Non Operating Income Expenses
0.07
-88.38%
0.64
-40.58%
1.07
+160.19%
0.41
Gain On Sale Of Security
-1.76
-121.21%
8.28
+190.36%
-9.16
+68.06%
-28.68
Gain On Sale Of Business
—
—
-1.12
0.00
Tax Provision
0.00
0.00
0.00
-100.00%
0.10
Tax Rate For Calcs
0.00
0.00
0.00
-100.00%
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
+100.00%
-7.17
Net Income Including Noncontrolling Interests
-88.34
-297.39%
-22.23
+89.30%
-207.73
+44.02%
-371.05
Net Income From Continuing Operation Net Minority Interest
-46.27
+6.90%
-49.70
+39.56%
-82.22
+41.77%
-141.20
Net Income From Continuing And Discontinued Operation
-46.27
-108.14%
-22.23
+89.30%
-207.73
+44.02%
-371.05
Net Income Continuous Operations
-88.34
-77.76%
-49.70
+39.56%
-82.22
+41.77%
-141.20
Net Income Discontinuous Operations
0.00
-100.00%
27.47
+121.88%
-125.51
+45.39%
-229.85
Minority Interests
42.07
0.00
0.00
—
Normalized Income
-44.51
-0.39%
-44.34
+11.34%
-50.01
+58.21%
-119.69
Net Income Common Stockholders
-46.27
-108.14%
-22.23
+89.30%
-207.73
+44.02%
-371.05
Diluted EPS
—
-0.28
+88.17%
-2.33
+44.94%
-4.24
Basic EPS
—
-0.28
+88.17%
-2.33
+44.94%
-4.24
Basic Average Shares
—
81.19
-8.42%
88.65
+7.44%
82.52
Diluted Average Shares
—
81.19
-8.42%
88.65
+7.44%
82.52
Diluted NI Availto Com Stockholders
-46.27
-108.14%
-22.23
+89.30%
-207.73
+44.02%
-371.05
Earnings From Equity Interest
0.00
+100.00%
-1.04
+90.90%
-11.40
+82.38%
-64.71
Total Other Finance Cost
—
—
—
—
Line Item Trend 2024-12-31 2023-12-31
Total Assets
212.68
-42.35%
368.92
Current Assets
176.69
-46.44%
329.91
Cash Cash Equivalents And Short Term Investments
173.40
-44.38%
311.73
Cash And Cash Equivalents
68.26
-76.58%
291.51
Other Short Term Investments
105.14
+419.93%
20.22
Receivables
1.17
-36.06%
1.83
Accounts Receivable
—
—
Gross Accounts Receivable
—
—
Allowance For Doubtful Accounts Receivable
—
—
Other Receivables
0.13
-92.91%
1.83
Taxes Receivable
—
0.66
Accrued Interest Receivable
1.04
0.00
Inventory
—
—
Prepaid Assets
2.12
+216.87%
0.67
Restricted Cash
—
0.00
Assets Held For Sale Current
0.00
-100.00%
15.68
Total Non Current Assets
35.99
-7.75%
39.01
Net PPE
3.80
-31.62%
5.55
Gross PPE
3.80
-41.73%
6.52
Accumulated Depreciation
-0.22
+76.76%
-0.96
Properties
0.00
0.00
Machinery Furniture Equipment
0.42
-77.30%
1.87
Construction In Progress
—
0.00
Other Properties
3.80
+0.56%
3.78
Leases
0.00
-100.00%
0.87
Goodwill And Other Intangible Assets
—
16.66
Goodwill
—
0.00
Other Intangible Assets
—
16.66
Investments And Advances
30.82
0.00
Long Term Equity Investment
—
1.70
Other Non Current Assets
1.36
-95.92%
33.46
Total Liabilities Net Minority Interest
11.52
-90.88%
126.34
Current Liabilities
8.45
-85.46%
58.14
Payables And Accrued Expenses
7.53
-4.04%
7.85
Payables
—
11.98
Other Payable
—
7.03
Current Accrued Expenses
7.53
-4.04%
7.85
Current Debt And Capital Lease Obligation
0.82
+30.35%
0.63
Current Debt
—
4.23
Current Capital Lease Obligation
0.82
+30.35%
0.63
Current Deferred Liabilities
0.11
-93.30%
1.58
Current Deferred Revenue
0.11
-93.30%
1.58
Other Current Liabilities
0.11
-99.79%
49.67
Total Non Current Liabilities Net Minority Interest
3.07
-95.50%
68.19
Liabilities Heldfor Sale Non Current
0.00
-100.00%
50.98
Long Term Debt And Capital Lease Obligation
3.07
-5.98%
3.26
Long Term Debt
—
8.31
Long Term Capital Lease Obligation
3.07
-5.98%
3.26
Non Current Deferred Liabilities
0.00
-100.00%
0.11
Non Current Deferred Revenue
0.00
-100.00%
0.11
Other Non Current Liabilities
—
—
Stockholders Equity
201.16
-17.08%
242.58
Common Stock Equity
201.16
-17.08%
242.58
Capital Stock
0.02
+0.00%
0.02
Common Stock
0.02
+0.00%
0.02
Share Issued
196.33
+1.16%
194.07
Ordinary Shares Number
187.45
+0.99%
185.61
Treasury Shares Number
8.87
+4.88%
8.46
Additional Paid In Capital
1,460.02
-0.99%
1,474.61
Retained Earnings
-1,286.04
-1.76%
-1,263.81
Gains Losses Not Affecting Retained Earnings
33.38
-16.06%
39.77
Treasury Stock
6.22
-22.26%
8.01
Other Equity Adjustments
33.38
-16.06%
39.77
Total Equity Gross Minority Interest
201.16
-17.08%
242.58
Total Capitalization
201.16
-17.08%
242.58
Working Capital
168.24
-38.09%
271.77
Invested Capital
201.16
-17.08%
242.58
Total Debt
3.88
-0.13%
3.89
Capital Lease Obligations
3.88
-0.13%
3.89
Net Tangible Assets
201.16
-17.08%
242.58
Tangible Book Value
201.16
-17.08%
242.58
Available For Sale Securities
30.82
—
Derivative Product Liabilities
0.00
-100.00%
13.85
Duefrom Related Parties Current
—
—
Dueto Related Parties Current
—
4.95
Investmentin Financial Assets
30.82
0.00
Line Of Credit
—
4.23
Other Inventories
—
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-20.60
+60.89%
-52.67
+27.55%
-72.70
-46.62%
-49.58
Cash Flow From Continuing Operating Activities
-20.60
+60.89%
-52.67
+27.55%
-72.70
-46.62%
-49.58
Net Income From Continuing Operations
-88.34
-77.76%
-49.70
+39.56%
-82.22
+41.77%
-141.20
Depreciation Amortization Depletion
0.86
-12.47%
0.98
-7.82%
1.06
-25.02%
1.42
Depreciation
0.86
-12.47%
0.98
-7.82%
1.06
-25.02%
1.42
Amortization Cash Flow
—
—
0.11
-2.67%
0.11
Depreciation And Amortization
0.86
-12.47%
0.98
-7.82%
1.06
-25.02%
1.42
Amortization Of Intangibles
—
—
0.11
-2.67%
0.11
Other Non Cash Items
42.07
+239.61%
12.39
—
2.25
Stock Based Compensation
5.97
+406.52%
-1.95
-119.04%
10.24
-22.13%
13.15
Asset Impairment Charge
0.00
-100.00%
1.25
-94.59%
23.04
0.00
Operating Gains Losses
-3.40
+73.52%
-12.82
-202.42%
12.52
-78.99%
59.61
Gain Loss On Investment Securities
-3.41
+75.37%
-13.85
-1339.00%
1.12
+122.05%
-5.07
Unrealized Gain Loss On Investment Securities
5.16
0.00
+100.00%
-0.22
+88.36%
-1.90
Gain Loss On Sale Of PPE
0.02
+245.45%
-0.01
0.00
+100.00%
-0.03
Change In Working Capital
17.07
+707.40%
-2.81
+92.43%
-37.12
-317.19%
17.09
Change In Receivables
—
0.00
0.00
-100.00%
1.55
Changes In Account Receivables
—
0.00
0.00
+100.00%
-2.75
Change In Inventory
—
—
0.00
-100.00%
3.95
Change In Prepaid Assets
-0.70
+63.08%
-1.90
-6900.00%
0.03
+101.56%
-1.80
Change In Payables And Accrued Expense
18.08
+8588.73%
-0.21
+99.40%
-35.68
-294.58%
18.34
Change In Other Working Capital
—
—
2.51
-67.09%
7.62
Change In Other Current Liabilities
-0.30
+56.20%
-0.69
+52.76%
-1.47
-48.23%
-0.99
Investing Cash Flow
104.97
+177.17%
-136.01
-796.96%
-15.16
-192.74%
-5.18
Cash Flow From Continuing Investing Activities
104.97
+177.17%
-136.01
-796.96%
-15.16
-192.74%
-5.18
Net PPE Purchase And Sale
0.04
+185.71%
0.01
+108.54%
-0.16
+92.16%
-2.09
Purchase Of PPE
-0.01
+85.42%
-0.05
+70.73%
-0.16
+92.16%
-2.09
Sale Of PPE
0.05
-24.19%
0.06
0.00
0.00
Capital Expenditure
-0.01
+85.42%
-0.05
+70.73%
-0.16
+92.16%
-2.09
Net Investment Purchase And Sale
104.92
+177.13%
-136.03
-806.86%
-15.00
-385.59%
-3.09
Purchase Of Investment
-49.96
+79.68%
-245.86
-145.86%
-100.00
+86.97%
-767.51
Sale Of Investment
154.88
+41.02%
109.83
+29.22%
85.00
-88.88%
764.42
Net Business Purchase And Sale
—
—
-0.82
0.00
Purchase Of Business
—
—
-0.85
0.00
Gain Loss On Sale Of Business
—
—
1.12
0.00
Financing Cash Flow
57.73
+17331.34%
-0.34
+95.93%
-8.24
-310.56%
3.91
Cash Flow From Continuing Financing Activities
57.73
+17331.34%
-0.34
+95.93%
-8.24
-310.56%
3.91
Net Issuance Payments Of Debt
—
—
9.86
+259.04%
2.75
Issuance Of Debt
—
—
16.77
+510.25%
2.75
Repayment Of Debt
—
—
-6.90
0.00
Long Term Debt Issuance
—
—
—
—
Long Term Debt Payments
—
—
—
—
Net Long Term Debt Issuance
—
—
—
—
Short Term Debt Issuance
—
—
16.77
+510.25%
2.75
Short Term Debt Payments
—
—
-6.90
0.00
Net Short Term Debt Issuance
—
—
9.86
+259.04%
2.75
Net Common Stock Issuance
61.71
+18522.09%
-0.34
+96.12%
-8.64
-187.56%
-3.01
Common Stock Payments
0.00
+100.00%
-0.34
+96.12%
-8.64
-187.56%
-3.01
Repurchase Of Capital Stock
0.00
+100.00%
-0.34
+96.12%
-8.64
-187.56%
-3.01
Proceeds From Stock Option Exercised
0.20
0.00
-100.00%
0.41
-94.12%
6.92
Net Other Financing Charges
-4.19
—
—
—
Changes In Cash
142.09
+158.48%
-242.98
-43.01%
-169.90
-85.70%
-91.49
Effect Of Exchange Rate Changes
0.28
-51.83%
0.57
-88.97%
5.20
-63.39%
14.20
Beginning Cash Position
68.26
-78.03%
310.67
-34.65%
475.37
-13.99%
552.67
End Cash Position
210.63
+208.56%
68.26
-78.03%
310.67
-34.65%
475.37
Free Cash Flow
-20.60
+60.92%
-52.72
+27.65%
-72.86
-41.00%
-51.67
Interest Paid Supplemental Data
—
0.00
-100.00%
0.10
0.00
Income Tax Paid Supplemental Data
—
0.00
0.00
-100.00%
0.10
Common Stock Issuance
61.71
0.00
0.00
0.00
Earnings Losses From Equity Investments
0.00
-100.00%
1.04
-90.90%
11.40
-82.38%
64.71
Issuance Of Capital Stock
61.71
0.00
0.00
0.00
Net Preferred Stock Issuance
—
—
—
—
Preferred Stock Issuance
—
—
—
—
Sale Of Business
—
—
0.03
0.00
Cash Flow From Discontinued Operation
0.00
+100.00%
-53.96
+26.89%
-73.80
-81.59%
-40.64
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category